7OC0 Stock Chart & Stats
€2.66
€0.00(0.00%)
At close: 4:00 PM EST
€2.66
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.48 - €7.35
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€134.08M
Enterprise Value€87.36
Total Cash (Recent Filing)€28.20M
Total Debt (Recent Filing)€3.07M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 06, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding32,290,170
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.18Price Target Upside245.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.83
Revenue Forecast (FY)€1.89M
Bulls Say, Bears Say
Bulls Say
FDA Submission And EngagementA late‑March FDA submission with ongoing productive engagement materially reduces regulatory uncertainty versus pre‑submission stages. Continued interaction and an expectation of first U.S. orders later this year create a durable path to scaled commercial revenues and removes a key binary risk over the next 2–6 months.
Medicare Reimbursement BenchmarkAn established Medicare reimbursement rate provides a structural pricing and revenue anchor for U.S. commercialization, improving revenue predictability and payer economics. This durable reimbursement support increases the likelihood of hospital adoption and underpins long‑term ASP and margin assumptions for test volumes.
Clinical Adoption Pipeline (GALACTIC Registry)Growing registry participation at transplant centers builds a durable demand funnel and clinical validation pathway. A 21% increase in weeks signals accelerating clinician engagement and creates recurring lab service volume potential and evidence generation that supports sustained commercial rollout over months.
Bears Say
Sharp Revenue Decline And Negative Gross ProfitA >50% TTM revenue decline and a negative gross profit indicate the core business is not generating sustainable top‑line or product economics. This structural revenue weakness means the company must materially scale tests or lab services to reach break‑even, making near‑term operational recovery a multi‑quarter challenge.
Persistent High Cash BurnConsistent multi‑year negative operating and free cash flow of roughly $24–27M TTM shows the business is not self‑funding and depends on external capital. This structural cash consumption constrains strategic flexibility, risks dilution on future raises, and pressures execution timelines for commercialization investments.
Negative Stockholders' EquityA shift to negative stockholders' equity reflects cumulative losses that weaken the balance sheet and reduce financial flexibility. Negative equity increases refinancing and dilution risk, limits borrowing capacity, and makes the company more sensitive to capital‑market conditions during the crucial commercialization phase.
Insight Molecular Diagnostics News
7OC0 FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was €2.48 and its highest was €7.35 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is €134.08M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on May 13, 2026. The company reported -€0.105 earnings per share for the quarter, beating the consensus estimate of -€0.23 by €0.124.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.21.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,290,170 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -€0.105 in its last earnings report, beating expectations of -€0.23. Following the earnings report the stock price went down -0.948%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in DE:7OC0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.18 (245.04% Upside)
€9.18 (245.04% Upside)
Insider Transactions
Bought Shares
Worth €2.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.02%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
7OC0 Stock 12 Month Forecast
Average Price Target
€9.18
▲(245.04% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Elutia
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―